Fujirebio Diagnostics
Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pioneered and introduced the CA125 test, the first FDA-approved ovarian cancer biomarker, over 25 years ago. Fujirebio Diagnostics specializes in the clinical development, manufacturing, and commercialization of in vitro diagnostic products for the management of human disease states, with an emphasis in oncology.
Content by Fujirebio Diagnostics
|2 min read
Fujirebio Receives 510(k) Clearance for Lumipulse® G pTau 217/ β-Amyloid 1–42 Plasma Ratio IVD Test for Alzheimer’s Disease
First blood-based in vitro diagnostic test to receive FDA clearance to help identify patients with amyloid pathology associated with Alzheimer’s disease
|1 min read
Fujirebio Diagnostics Announces Initiation of Clinical Testing for SARS-CoV-2 Antigen Assay
As a leading provider of immunoassays to the diagnostic industry, Fujirebio, as a global team, is joining the fight to combat the COVID-19 pandemic with the goal of providing the first fully automated antigen testPage 1 of 1
